<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007279</url>
  </required_header>
  <id_info>
    <org_study_id>ROMA55</org_study_id>
    <nct_id>NCT01007279</nct_id>
  </id_info>
  <brief_title>Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)</brief_title>
  <acronym>ROMA</acronym>
  <official_title>ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after
      otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch
      occlusion, intimal dissection and coronary spasm, a possible aetiology of myonecrosis after
      PCI might be distal embolization of atherogenic materials from plaque disruption,(2 )causing
      obstruction of blood flow at capillary level resulting in micro-infarction.(3,4 )Recent
      studies have suggested that pretreatment with Atorvastatin may be associated with a reduction
      in infarct size after elective PCI. (5-7 ).Actually the standard pretreatment in patients
      undergoing elective coronary-PCI and already treated with aspirin is copidogrel loading dose
      administration before procedure.(8,9 ) The investigators hypothesized that a high (40mg)
      loading dose of Rosuvastatin administered within 24h before the procedure may be effective in
      reducing the rate of periprocedural MI.Therefore, the investigators will conduct a single
      center,prospective randomized study to assess whether a single,high (40mg) loading
      (within24h)dose of Rosuvastatin is effective in preventing elevation of biomarkers of MI
      after elective coronary stent implantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial enzymes arise</measure>
    <time_frame>6-12-24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>1-6-9 MONTHS</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Periprocedural Myocardial Necrosis</condition>
  <arm_group>
    <arm_group_label>CLOPIDOGREL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ROSUVASTATIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ROSUVASTATIN</intervention_name>
    <description>40 mg before procedure</description>
    <arm_group_label>CLOPIDOGREL</arm_group_label>
    <arm_group_label>ROSUVASTATIN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable angina

        Exclusion Criteria:

          -  Baseline myocardial enzyme rise
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00166</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2009</study_first_posted>
  <last_update_submitted>October 25, 2010</last_update_submitted>
  <last_update_submitted_qc>October 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>GENNARO SARDELLA</name_title>
    <organization>POLICLINICO UMBERTO I-SAPIENZA UNIVERSITY OF ROME</organization>
  </responsible_party>
  <keyword>Percutaneous angioplasty</keyword>
  <keyword>Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

